1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Teva’s Generic Viagra Launch Will Be Offset By Generic Cialis

 
• By Brenda Sandburg

Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.

Teva Pharmaceuticals USA Inc.’s patent settlement agreement with Pfizer Inc.will enable it to launch the first generic version of Viagra (sildenafil) two years and four months before Pfizer’s use patent expires. But it will enter the market just as the patent on Eli Lilly & Co.’s competing erectile dysfunction blockbuster Cialis (tadalafil) expires.

Under the terms of the settlement, announced on Dec. 17, Teva will be able to market its product on Dec....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

‘Brainless’ US MFN Policy Could Drive Pharma Investment To Europe

 
• By Francesca Bruce

European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 
• By Urtė Fultinavičiūtė

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

HHS Secretary Favors Regenerative Medicine Over Traditional Pharma: Blessing And Curse?

 
• By Sarah Karlin-Smith

Cell and gene therapy developers may not have to contend with HHS Secretary Robert F. Kennedy Jr.’s animosity like the traditional pharma industry, but his disinterest in distinguishing between the good and bad actors in the space could backfire.